I
IMPACT BIOMEDICAL INC.
IBOCIK 0001834105NYSENon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsNevadaFY ends Dec 31
Period
FY 2025
Revenue
$32.0K
Net Income
$-11.84M
Total Assets
$17.41M
Equity
$12.61M
Shares Out
107.82M
Op. Cash Flow
$-1.89M
Business
Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies in biopharmaceuticals, over-the-counter wellness offerings, and drug discovery targeting neurological, oncologic, and inflammatory diseases. Core offerings include Linebacker (small-molecule polyphenol compounds for oncology and inflammatory disorders), Laetose (a sugar alternative with metabolic benefits), Functional Fragrance Formulation (3F, with antimicrobial and insect-repellent applications), and Equivir (antiviral polyphenol blend). The company operates through four principal subsidiaries and commercializes technologies via licensing agreements, milestone payments, and royalty arrangements with pharmaceutical and consumer packaged goods partners, plus acquired air-purification technology for direct revenue generation.
Summary from 10-K filed 2026-03-11
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Total revenue | 32,000 | — | — | 50,000 | |
| Cost of revenue | 424,000 | — | — | — | |
| Sales, general and administrative compensation (inclusive of stock-based compensation) | 873,000 | 718,000 | 315,000 | 325,000 | |
| Sales and marketing | 24,000 | 633,000 | 65,000 | — | |
| Professional Fees | 1 | 446,000 | 724,000 | 722,000 | |
| Research and development | 340,000 | 278,000 | 2 | 1 | |
| Depreciation and Amortization | 1 | 1 | 1 | 1 | |
| Rent and utilities | 74,000 | 32,000 | — | — | |
| Impairment of goodwill | — | 25 | — | 0 | |
| Impairment of fixed assets | — | 263,000 | — | — | |
| Loss on disposal of fixed assets | 12,000 | — | — | — | |
| Other operating expenses | 417,000 | 171,000 | 119,000 | — | |
| Total costs and expenses | 4 | 29 | — | — | |
| Operating loss | −4 | −29 | −4 | −3 | |
| Interest income | 13,000 | 13,000 | 13,000 | — | |
| Change in fair value of note payable, related party | −9 | 5 | — | — | |
| Interest expense | −793,000 | −1 | −444,000 | −462,000 | |
| Loss from operations before income taxes | −14 | −25 | −4 | −8 | |
| Income tax benefit (expense) | 3 | −33,000 | — | 621,000 | |
| Net loss | −12 | −25 | −4 | — | |
| Loss from operations attributed to noncontrolling interest | 32,000 | 62,000 | 71,000 | — | |
| Net loss attributable to common stockholders | −12 | −25 | −4 | −7 | |
| Basic (per share) | −0.38 | −2.3 | −0.07 | −0.1 | |
| Diluted (per share) | −0.38 | −2.3 | −0.07 | −0.1 | |
| Basic (shares) | 32 | 11 | 60 | 70 | |
| Diluted (shares) | 32 | 11 | 60 | 70 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3,000 | 2 | 1,000 | 2,000 | — | |
| Accounts receivable | 5,000 | — | — | — | — | |
| Inventory | 63,000 | — | — | — | — | |
| Current portion of notes receivable | 198,000 | 184,000 | 203,000 | 16,000 | — | |
| Prepaid expenses and other current assets | 142,000 | 265,000 | — | 104,000 | — | |
| Total current assets | 411,000 | 2 | 332,000 | 122,000 | — | |
| Property, plant and equipment, net | — | 17,000 | 287,000 | 276,000 | — | |
| Notes receivable | — | 17,000 | — | 190,000 | — | |
| Other intangible assets, net | 17 | 18 | 19 | 20 | — | |
| Total assets | 17 | 20 | 45 | 46 | — | |
| Accounts payable | 347,000 | 314,000 | 832,000 | 539,000 | — | |
| Accrued expenses | 194,000 | 194,000 | 230,000 | 63,000 | — | |
| Due to related party | 621,000 | 399,000 | — | — | — | |
| Note payable, related party | — | 9 | 12 | 10 | — | |
| Total current liabilities | 1 | 10 | 13 | 11 | — | |
| Deferred tax liability, net | 688,000 | 3 | 3 | 3 | — | |
| Total liabilities | 2 | 13 | 16 | 14 | — | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 100,000,000 shares authorized, zero shares issued and outstanding (60,496,041 on December 31, 2024); Liquidation value $0.001 per share, zero aggregate. $60,496,041,000 on December 31, 2024). | — | 60,000 | 60,000 | — | — | |
| Common stock, $0.001 par value; 4,000,000,000 shares authorized, 104,621,231 shares issued and outstanding (11,503,955 on December 31, 2024) | 105,000 | 11,000 | 10,000 | 70,000 | — | |
| Additional paid-in capital | 62 | 42 | 38 | — | — | |
| Accumulated deficit | −50 | −38 | −13 | −9 | — | |
| Total stockholders equity of the Company | 13 | 4 | 25 | 30 | — | |
| Non-controlling interest in subsidiaries | 3 | 3 | 3 | 3 | — | |
| Total stockholders equity | 16 | 7 | 28 | 33 | 40 | |
| Total liabilities and stockholders equity | 17 | 20 | 45 | 46 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Depreciation and amortization | 1 | 1 | 1 | 1 | |
| Stock based compensation | 13,000 | 19,000 | — | — | |
| Issuance of shares for professional services rendered | 190,000 | — | — | — | |
| Accrued interest on notes payable | 793,000 | 1 | — | — | |
| Change in deferred tax liability | −3 | 33,000 | — | −621,000 | |
| Impairment of inventory | 419,000 | — | — | — | |
| Loss on disposal of fixed assets | 12,000 | — | — | — | |
| Accounts receivable | −1,000 | 128,000 | — | — | |
| Inventory | 7,000 | — | — | — | |
| Prepaid expenses and other current assets | 126,000 | −265,000 | 104,000 | −60,000 | |
| Accounts payable | 470,000 | −436,000 | 293,000 | 424,000 | |
| Accrued expenses | −2,000 | −35,000 | 167,000 | 57,000 | |
| Net cash used operating activities | −2 | −3 | −3 | −2 | |
| Payments received on notes receivable | 3,000 | 2,000 | 3,000 | — | |
| Net cash provided by investing activities | 3,000 | 2,000 | −15,000 | −349,000 | |
| Borrowings from related party | 184,000 | — | 3 | 3 | |
| Payments to related party | −293,000 | — | — | — | |
| Borrowings of note payable, related party | — | 1 | — | — | |
| Issuances of common stock, net of issuance costs | — | 4 | — | — | |
| Net cash (used) provided by financing activities | −109,000 | 5 | 3 | 3 | |
| Net increase (decrease) in cash | −2 | 2 | −1,000 | −44,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is IMPACT BIOMEDICAL INC.'s CIK number?
IMPACT BIOMEDICAL INC.'s SEC CIK number is 0001834105 (1834105). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find IMPACT BIOMEDICAL INC.'s SEC filings?
All of IMPACT BIOMEDICAL INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.